Home/Pipeline/FINVAC COVID-19

FINVAC COVID-19

COVID-19 (SARS-CoV-2)

Phase 1Active

Key Facts

Indication

COVID-19 (SARS-CoV-2)

Phase

Phase 1

Status

Active

Company

Rokote Laboratories

About Rokote Laboratories

Rokote Laboratories is a private, pre-revenue biotech developing a novel intranasal vaccine platform. Its FINVAC technology uses an adenoviral vector backbone to create vaccines that target the nasal mucosa, aiming to block infection and transmission of respiratory viruses like SARS-CoV-2, influenza, and RSV. The company is currently in Phase I clinical development with its lead COVID-19 vaccine and is positioning its platform for pandemic preparedness and seasonal respiratory disease. Leadership combines expertise in virology, immunology, and clinical operations.

View full company profile

Therapeutic Areas

Infectious Diseases Respiratory Diseases

Other COVID-19 (SARS-CoV-2) Drugs

Drug	Company	Phase	Status
IN-006	Inhalon Biopharma	Phase 1b	Active
IN-007	Inhalon Biopharma	Preclinical	Active
SAB-185	SAB Biotherapeutics	Phase 2/3	Completed